Prognostic significance of biologic factors in squamous cell carcinoma of the esophagus

Cancer

Volumn 86, Issue 8, 1999, Pages 1396-1405

  Ikeda, Goh ^a   Isaji, Shuji ^a   Das, Bidhan Chandra ^a   Watanabe, Masatoshi ^a   Kawarada, Yoshifumi ^a  

^a MIE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Esophageal carcinoma; Ki 67; p53; Prognostic factor

Indexed keywords

KI 67 ANTIGEN;

ADULT; AGED; ARTICLE; ESOPHAGUS CARCINOMA; FEMALE; GENE AMPLIFICATION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LABELING INDEX; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PLOIDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RISK FACTOR; SQUAMOUS CELL CARCINOMA;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CARCINOMA, SQUAMOUS CELL; CYCLIN D1; DNA, NEOPLASM; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PLOIDIES; PROGNOSIS; SURVIVAL ANALYSIS; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0033570006     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19991015)86:8<1396::AID-CNCR3>3.0.CO;2-H     Document Type: Article

References (46)

1. Parkin DM, Laara E, Muir CS. Estimates of the world-wide frequency of sixteen major cancers in 1980. Int J Cancer 1988;41:184-97.
2. Sugimachi K, Ohno S, Matsuda H, Mori M, Matsuoka H, Kuwano H. Clinicopathologic study of early stage esophageal carcinoma. Surgery 1989;105:706-10.
3. Kato H. Diagnosis and treatment of esophageal neoplasms. Jpn J Cancer Res 1995;86:993-1009.
4. Earlam R, Cunha-Melo JR. Oesophageal squamous cell carcinoma: 1. A critical review of surgery. Br J Surg 1980;67:381-90.
5. Hollstein MC, Metcalf RA, Welsh JA, Montesano R, Harris CC. Frequent mutation of the p53 gene in human esophageal cancer. Proc Natl Acad Sci USA 1990;87:9958-61.
6. Miyazaki S, Sasano H, Shiga K, Sawai T, Nishihira T, Okamoto H, et al. Analysis of c-myc oncogene in human esophageal carcinoma: immunohistochemistry, in situ hybridization and Northern and Southern blot studies. Anticancer Res 1992;12:1747-55.
7. Huang Y, Meltzer SJ, Yin J, Tong Y, Chang EH, Srivastava S, et al. Altered messenger RNA and unique mutational profiles of p53 and Rb in human esophageal carcinomas. Cancer Res 1993;53:1889-94.
8. Kanda Y, Nishiyama Y, Shimada Y, Imamura M, Nomura H, Hiai H, et al. Analysis of gene amplification and overexpression in human esophageal-carcinoma cell lines. Int J Cancer 1994;58:291-7.
9. Yoshida K, Kawami H, Kuniyasu H, Nishiyama M, Yasui W, Hirai T, et al. Coamplification of cyclin D, hst-1 and int-1 genes is a good biological marker of high malignancy for human esophageal carcinomas. Oncol Rep 1994;1:493-6.
10. Kitagawa Y, Ueda M, Ando N, Shinozawa Y, Shimizu N, Abe O. Significance of int-2/ hst-1 coamplification as a prognostic factor in patients with esophageal squamous carcinoma. Cancer Res 1994;54:1504-8.
11. Jiang W, Kahn SM, Tomita N, Zhang YJ, Lu SH, Weinstein B. Amplification and expression of human cyclin D gene in esophageal cancer. Cancer Res 1992;52:2980-3.
12. Adelaide J, Monges G, Derderiant C, Seitz JF, Birnbaum D. Oesophageal cancer and amplification of the human cyclin D gene CCND1/PRAD1. Br J Cancer 1995;71:64-8.
13. Naitoh H, Shibata J, Kawaguchi A, Kodama M, Hattori T. Overexpression and localization of cyclin D1 mRNA and antigen in esophageal cancer. Am J Pathol 1995;146:1161-9.
14. Motokura T, Bloom T, Kim YG, Jueppner H, Ruderman J, Kronenberg H, et al. A novel cyclin encoded by bcl-1 linked candidate oncogene. Nature 1991;350:512-5.
15. Quelle DE, Ashmun RA, Shurtleff SA, Kato J, Bar-Sagi D, Roussel MF, et al. Overexpression of mouse D-type cyclins accelerates G1 phase in rodent fibroblasts. Genes Dev 1993; 7:1559-71.
16. Jiang W, Kahn SM, Zhou P, Zhang YJ, Cacace AM, Infante AS, et al. Overexpression of cyclin D1 in rat fibroblasts causes abnormalities in growth control, cell cycle progression, and gene expression. Oncogene 1993;73:3447-57.
17. Watanabe H, Jass JR, Sobin LH., editors. World Health Organization. International histological classification of the tumors: histological typing of oesophageal and gastric tumors, 2nd ed. Berlin: Springer-Verlag, 1992.
18. Sobin LH, Wittekind C, editors. UICC TNM classification of malignant tumours. 5th ed. New York: John Wiley & Sons, Inc., 1997.
19. Hedley DW, Friedlander ML, Taylar IW, Rugg CA, Musgrove EA. Method for analysis of cellular DNA content of paraffin-embedded pathological material using flow cytometry. J Histochem Cytochem 1983;31,1333-5.
20. Morita M, Kuwano H, Matsuda H, Moriguchi S, Sugimachi K. Prognostic significance of argyrophilic nuclear organizer regions in esophageal carcinoma. Cancer Res 1991;51:5339-41.
21. Sasano H, Miyazaki S, Nishihara T, Sawai T, Nagura H. The proliferative cell fraction in cytology specimens, a study of human esophageal carcinoma. Am J Clin Pathol 1992;98: 161-6.
22. Koga Y, Kuwano H, Sugimachi K. Biologic characteristics of esophageal epithelial dysplasia assessed by proliferating cell nuclear antigen. Cancer 1996;77:237-44.
23. Kurki P, Lotz M, Ogata K, Tan EM. Proliferating cell nuclear antigen (PCNA)/cyclin activated human T lymphocytes. J Immunol 1987;138:4114-20.
24. Diebold J, Lai MD, Lohrs U. Analysis of proliferative activity in colorectal mucosa by immunohistochemical detection of proliferating cell nuclear antigen (PCNA). Methodological aspects and application to routine diagnostic material. Virchows Arch B Cell Pathol Incl Mol Pathol 1992;62:283-9.
25. Schluter C, Duchrow M, Wohlenberg C, Becker MH, Key G, Flad HD, et al. The cell proliferation-associated antigen of antibody Ki-67: a very large, ubiquitous nuclear protein with numerous repeated elements, representing a new kind of cell cycle-maintaining proteins. J Cell Biol 1993;123:513-22.
26. Youssef EM, Matusda T, Takada N, Osugi H, Higashino M, Kinoshita H, et al. Prognostic significance of the MIB-1 proliferation index for patients with squamous cell carcinoma of the esophagus. Cancer 1995;76:358-66.
27. Kawamura T, Goseki N, Koike M, Takizawa T, Endo M. Acceleration of proliferative activity of esophageal squamous cell carcinoma with invasion beyond the mucosa. Cancer 1996;77:843-9.
28. Suzuki H, Matsumoto K, Terabe M. Ki-67 antibody labeling index in colorectal carcinoma. J Clin Gastroenterol 1992; 15(4):317-20.
29. Lane DP. Cancer. p53, guardian of the genome. Nature 1992;358:15-6.
30. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991;253:49-53.
31. Wang DY, Xiang YY, Tanaka M, Li XR, Li JL, Shen Q, et al. High prevalence of p53 protein overexpression in patients with esophageal cancer in Lixian, China, and its relationship to progression and prognosis. Cancer 1994;74:3089-96.
32. Shimaya K, Shiozaki H, Inoue M, Tahara H, Monden T, Shimano T, et al. Significance of p53 expression as a prognostic factor in oesophageal squamous cell carcinoma. Virchows Arch A Pathol Anat Histopathol 1993;422:271-6.
33. Coggi G, Bosari S, Roncalli M, Graziani D, Bossi P, Viale G, et al. p53 protein accumulation and p53 gene mutation in esophageal carcinoma: a molecular and immunohistochemical study with clinicopathologic correlations. Cancer 1997;79:425-32.
34. Sharbia M, Porschen R, Borchard F, Holstmann O, Willers R, Gabbert HE. p53 protein expression and prognosis in squamous cell carcinoma of the esophagus. Cancer 1994; 74:2218-22.
35. Ribeiro U, Finkelstein SD, Safatle-Ribeiro AV, Landreneau RJ, Clarke MR, Bakker A, et al. p53 sequence analysis predicts treatment response and outcome of patients with esophageal carcinoma. Cancer 1998;83:7-18.
36. Momand J, Zambetti GP, Olson DC, George D, Levine AJ. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992;69:1237-45.
37. Vogelstein B, Kinzler KW. p53 function and dysfunction. Cell 1992;70:523-6.
38. Jiang W, Zhang Y-J, Kahn SM, Hollstein MC, Santella RM, Lu S-H, et al. Altered expression of the cyclin D1 and retinoblastoma genes in human esophageal cancer. Proc Natl Acad Sci USA 1993;90:9026-30.
39. Gramlich TL, Fritsch CR, Maurer D, Eberle M, Gansler TS. Differential polymerase chain reaction assay of cyclin D1 gene amplification in esophageal carcinoma. Diagn Mol Pathol 1994;3:255-9.
40. Roncalli M, Bosari S, Marchetti A, Buttitta F, Bossi P, Graziani D, et al. Cell cycle-related gene abnormalities and product expression in esophageal carcinoma. Lab Invest 1998;78: 1049-57.
41. Yu JM, Yang LH, Guo-Qian, Chen YT, Li X, Zhong WX, et al. Flow cytometric analysis of DNA content in esophageal carcinoma: correlation with histologic and clinical features. Cancer 1989;64:80-2.
42. Robey-Caffery SS, El-Naggar AK, Sahin AA, Bruner JM, Ro JY, Cleary KR. Prognostic factors in oesophageal squamous carcinoma: a study of histologic features, blood group expression, and DNA ploidy. Am J Clin Pathol 1991;95:844-9.
43. Patil P, Redkar A, Patel SG, Krishnamurthy S, Mistry RC, Deshpande RK, et al. Prognosis of operable squamous cell carcinoma of the oesophagus: relationship with clinicopathologic features and DNA ploidy. Cancer 1993;72:1305-12.
44. Haraguchi Y, Baba M, Takao S, Yoshinaka H, Hase S, Aikou T. Flow cytometric analysis of DNA heterogeneity in superficial carcinoma of the esophagus. Cancer 1995;75:914-9.
45. Minu AR, Endo M, Sanagawa M. Role of DNA ploidy patterns in esophageal squamous cell carcinoma. Cancer 1994; 74:578-85.
46. Holscher AH, Bollschweiler E, Schneider PM, Siewert JR. Prognosis of early esophageal cancer: comparison between adeno- and squamous cell carcinoma. Cancer 1995;76: 178-86.